
-
Oncolytics Biotech NasdaqCM:ONCY Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Location: 322 11th Avenue SW, Calgary, AB, T2R 0C5, Canada | Website: https://oncolyticsbiotech.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
18.06M
Cash
15.3M
Avg Qtr Burn
-6.499M
Short % of Float
2.61%
Insider Ownership
3.92%
Institutional Own.
1.53%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Pelareorep + paclitaxel + avelumab (Bavencio®) Details Breast cancer, Cancer | Phase 3 Initiation | |
Pelareorep + gemcitabine, nab-paclitaxel, atezolizumab Details Cancer, Pancreatic cancer | Phase 3 Initiation | |
Pelareorep + Retifanlimab Details Breast cancer, Triple-negative breast cancer | Phase 2 Update | |
Pelareorep + modified FOLFIRINOX +/- atezolizumab Details Cancer, metastatic pancreatic cancer | Phase 1/2 Data readout | |
Pelareorep + Atezolizumab (Tecentriq) Details Cancer, Anal cancer | Phase 1/2 Data readout | |
Pelareorep + Keytruda® Details Pancreatic cancer, Sarcoma | Failed Discontinued | |
Pelareorep +/- Atezolizumab Details Cancer, Breast cancer | Failed Discontinued |